Volume | 1,684,012 |
|
|||||
News | - | ||||||
Day High | 0.655 | Low High |
|||||
Day Low | 0.62 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Citius Pharmaceuticals Inc | CTXR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.65 | 0.62 | 0.655 | 0.6319 | 0.66 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,641 | 1,684,012 | $ 0.6348603 | $ 1,069,112 | - | 0.60 - 1.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:48:30 | 3 | $ 0.6397 | USD |
Citius Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
100.23M | 159.09M | - | 0 | -33.69M | -0.21 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Citius Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTXR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.78 | 0.95 | 0.62 | 0.7240603 | 7,178,198 | -0.1402 | -17.97% |
1 Month | 0.70 | 0.95 | 0.602 | 0.7078451 | 2,447,393 | -0.0602 | -8.60% |
3 Months | 0.75 | 1.07 | 0.602 | 0.7533459 | 1,481,074 | -0.1102 | -14.69% |
6 Months | 0.781 | 1.07 | 0.60 | 0.7491306 | 1,027,646 | -0.1412 | -18.08% |
1 Year | 1.12 | 1.40 | 0.60 | 0.8985386 | 1,060,378 | -0.4802 | -42.88% |
3 Years | 2.30 | 4.56 | 0.60 | 1.90 | 1,857,182 | -1.66 | -72.18% |
5 Years | 1.28 | 4.56 | 0.40 | 1.80 | 2,285,530 | -0.6402 | -50.02% |
Citius Pharmaceuticals Description
Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. |